Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.51 |
| ▸ | NPY1R | P25929 | 7/20 | 0.51 |
| ▸ | NPY2R | P49146 | 5/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.51 |
| ▸ | FURIN | P09958 | 5/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30339863 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30456880 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL29732335 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30305367 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30148454 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30945400 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL29799775 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL1527412 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30945410 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30305284 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059896-A1 | USE OF FURIN CONVERTASE INHIBITORS IN THE TREATMENT OF FIBROSIS AND SCARRING | RENOVO LIMITED | 2011-03-10 | — | — | US | disclosed |
| US-7700562-B2 | Use of —furin—“convertase” inhibitors in the treatment of fibrosis and scarring | RENOVO LIMITED (GB) | 2010-04-20 | — | — | US | disclosed |
| US-20090068174-A1 | THERAPEUTIC ALKALINE PROTEASE COMPOSITIONS AND USE IN FACILITATING THE TRANSPORT OF AGENTS ACROSS THE GASTROINTESTINAL MUCOSAL LINING | KANSAS UNIVERSITY MEDICAL CENTER RESEARCH INSTITUTE, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20080081035-A1 | Using aspergillus akaline protease as tool in treatment and prevention of infection, cardiovascular, rheumatic, soft tissue and skin disorders | NATIONAL ENZYME COMPANY (US) | 2008-04-03 | — | — | US | disclosed |
| US-20060052309-A1 | Use of convertase inhibitors in the treatment of fibrosis and scarring | RENOVO LIMITED (GB) | 2006-03-09 | — | — | US | disclosed |
| EP-1556080-A1 | USE OF CONVERTASE INHIBITORS IN THE TREATMENT OF FIBROSIS AND SCARRING | Renovo Limited (GB) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004009113-A1 | USE OF CONVERTASE INHIBITORS IN THE TREATMENT OF FIBROSIS AND SCARRING | RENOVO LIMITED (GB) | 2004-01-29 | — | — | WO | disclosed |